Loading
A phase 3 trial of Docetaxel, Trastuzumab, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.
Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer is a phase 3 interventional study registered as NCT00615602 by Hellenic Oncology Research Group, with 489 participants recorded, started 2004-10 and reaching its primary completion in 2012-05. Interventions recorded: Docetaxel, Trastuzumab, Epirubicin, Cyclophosphamide, 5-fluoruracil, Granulocyte-colony stimulating growth factor, Trastuzumab. Conditions recorded: Breast Cancer.
Linked to the drug Lenograstim because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hellenic Oncology Research Group, Lenograstim, Pegfilgrastim, Epirubicin and the tag pipeline.
Shares Hellenic Oncology Research Group, Lenograstim, Pegfilgrastim, Epirubicin and the tag pipeline.
Shares Epirubicin, Fluorouracil (5-FU), Docetaxel, Cyclophosphamide and the tag pipeline.
Shares Trastuzumab, Docetaxel, Cyclophosphamide, Breast cancer (all types) and the tag pipeline.
Shares Epirubicin, Docetaxel and the tag pipeline.
Shares Trastuzumab, Cyclophosphamide, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Docetaxel and the tag pipeline.
Shares Trastuzumab, Docetaxel, Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/